Envestnet Asset Management Inc Biocryst Pharmaceuticals Inc Transaction History
Envestnet Asset Management Inc
- $299 Billion
- Q1 2025
A detailed history of Envestnet Asset Management Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Envestnet Asset Management Inc holds 10,282 shares of BCRX stock, worth $103,539. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,282Holding current value
$103,539% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding BCRX
# of Institutions
292Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$218 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$201 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$89.9 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$87.6 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$78.7 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.87B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...